DocGo Raises SteadyMD Earnout Liability To $5 Million From $2.3 Million As Telehealth Revenue Outlook Improves
DocGo has increased its estimated contingent consideration liability for the SteadyMD acquisition from $2.3 million to $5 million, reflecting a more optimistic revenue outlook for the telehealth business. This adjustment resulted in a $2.7 million fair-value loss in the first half but indicates an expected improvement in SteadyMD's performance. The stronger outlook for SteadyMD is crucial for DocGo as it faces declining revenues from migrant-related government programs, making growth from new businesses vital for future financial health and liquidity.
Canaccord Genuity Group Reaffirms "Hold" Rating for DocGo (NASDAQ:DCGO)
Canaccord Genuity Group has reiterated its "Hold" rating for DocGo (NASDAQ:DCGO), maintaining a $1.00 price target, which implies an 85.9% upside from its current share price of $0.54. Analyst sentiment for DocGo is mixed, with a consensus "Hold" rating and an average target price of $2.38 among six analysts. DocGo's shares recently dropped 24.2% to $0.54, while institutional investors hold 56.44% of the company's stock.
DocGo stock price target maintained at $2.50 by Stifel
Stifel maintained a Buy rating and $2.50 price target for DocGo (NASDAQ:DCGO) despite the company reporting Q2 revenue and EBITDA below consensus. DocGo is acquiring Hicuity Health, a virtual care provider, which Stifel believes could be synergistic and accelerate growth. The firm views 2026 as a transition year as DocGo aims for breakeven EBITDA by the end of 2026 and trades at 0.1 times revenue, reflecting current risk and reward.
DocGo (NASDAQ:DCGO) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC has reaffirmed its "buy" rating for DocGo (NASDAQ:DCGO) and set a price target of $3.00, suggesting a potential upside of 322.48% from its current price. Despite this, the stock has an overall "Hold" rating from analysts with an average price target of $2.38. DocGo is an integrated healthcare company providing on-demand and mobile healthcare services through customized medical clinics and a digital care platform.
DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast
DocGo (NASDAQ:DCGO) shares dropped significantly after the company reported weaker-than-expected second-quarter 2026 results and substantially increased its projected full-year adjusted EBITDA loss. The mobile healthcare provider's revenue was impacted by the wind-down of migrant-related contracts, and its profitability outlook worsened, leading to investor concern. The acquisition of Hicuity Health also adds integration risk while the company faces a negative market backdrop and Nasdaq listing compliance issues.
DocGo Releases Q2 2026 Financial Results
DocGo Inc. reported a wider-than-expected diluted loss of $0.16 per share for Q2 2026 and revenue of $73.4 million, falling short of analyst expectations. The company attributes the miss to its restructuring efforts away from migrant services, though core operations excluding migrant programs showed a 19% revenue climb. DocGo provided full-year revenue guidance between $305.0 million and $310.0 million, and analyst consensus remains cautiously balanced with 4 buys and 4 holds.
DocGo posts Q2 miss, cuts adjusted EBITDA outlook
DocGo (NASDAQ:DCGO) reported a Q2 earnings and revenue miss, delivering a loss of -$0.16 per share against an estimated -$0.10, and revenue of $73.4 million versus a $75.4 million consensus. The company also significantly lowered its full-year adjusted EBITDA outlook to -$17 million to -$22 million. Despite the financial miss and outlook cut, DocGo's shares were up 1% in after-hours trading, possibly due to the announcement of its definitive agreement to acquire virtual care provider Hicuity Health.
DocGo (NASDAQ: DCGO) warns on liquidity as losses widen
DocGo (NASDAQ: DCGO) reported a net loss of $34.69 million on revenues of $148.98 million for the first six months of 2026, widening from a $24.37 million net loss on $176.45 million in revenue during the same period in 2025. The company also indicated a going-concern risk due to ongoing operating losses and non-compliance with a minimum liquidity covenant under its credit agreement. DocGo is actively negotiating with its lender and exploring cost-reduction and cash-preservation strategies, including a potential replacement term loan and shifting compensation to stock, to address its liquidity issues.
Earnings call transcript: DocGo misses Q2 2026 estimates as stock falls after hours
DocGo reported Q2 2026 results that missed Wall Street expectations, with an adjusted loss per share of $0.16 and revenue of $73.4 million. The company's stock fell 11.28% after hours despite a regular-session gain, due to the earnings miss, a wider full-year loss outlook, and plans for a Hicuity Health acquisition. DocGo aims for positive adjusted EBITDA run rate by the end of 2026, driven by revenue growth, margin recovery, and cost efficiencies.
DocGo to acquire virtual care company Hicuity Health
DocGo has announced its agreement to acquire Hicuity Health, a virtual care company, by assuming its $52 million existing debt. This deal will make Hicuity a wholly-owned subsidiary of DocGo's Ambulnz Holdings. The Series F preferred shareholder of Hicuity will receive DocGo shares, with potential for more if DocGo's market capitalization reaches $250 million within three years.
DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates
DocGo Inc. (DCGO) reported Q2 earnings of $0.16 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.04 per share. Despite this earnings beat, the company's revenues of $73.43 million missed the consensus estimate and were lower than the previous year. The stock has underperformed the S&P 500 year-to-date, and its future performance will likely depend on management's commentary and evolving earnings expectations.
DocGo (NASDAQ:DCGO) Posts Earnings Results, Misses Estimates By $0.06 EPS
DocGo (NASDAQ:DCGO) announced its quarterly earnings, reporting a loss of $0.16 per share, missing analyst expectations by $0.06, and revenue of $73.42 million, below the $75.35 million consensus. Despite the earnings miss, the stock rose 6.4% to $0.71, with trading volume exceeding its daily average. Analysts hold a "Hold" rating on DocGo with an average target price of $2.38, and institutional investors own 56.44% of the company's shares.
DocGo (NASDAQ: DCGO) to buy Hicuity virtual care business and tap $50M in loans
DocGo (NASDAQ: DCGO) announced an agreement to acquire virtual care provider Hicuity Health through a stock-for-equity transaction and the assumption of Hicuity's debt, which is estimated to be approximately $52 million. Perceptive Advisors has committed up to an additional $50 million in new senior secured term loans for DocGo. This acquisition is expected to add approximately $65 million in trailing-12-month revenue and $4.5 million in adjusted EBITDA for Hicuity Health, expanding DocGo's offerings into high-acuity virtual clinical care.
DocGo Inc. 2026: Revenue $73.42M, EPS ($0.16) — 10-Q Summary
DocGo Inc. reported a Q2 2026 revenue of $73.42M and a diluted loss per share of ($0.16), showing a decline compared to the prior year. This decrease was primarily due to the wind-down of migrant-related Mobile Health contracts, though Transportation Services saw modest growth and the company implemented measures like headcount reduction and AI investment to manage costs and pursue new opportunities.
DocGo agrees to acquire virtual care provider Hicuity Health, assumes $52M debt
DocGo announced its acquisition of virtual care provider Hicuity Health, including the assumption of approximately $52 million in Hicuity's debt. This move aims to expand DocGo's virtual care offerings, building on its previous acquisition of SteadyMD. The announcement coincided with DocGo's Q2 2026 earnings report, which showed a revenue decline due to the wind-down of migrant-related programs but strong growth in core business lines and record volumes.
Earnings To Watch: DocGo Inc (DCGO) Q2 2026 -- GF Value Sees 151% Upside
DocGo Inc (DCGO) is scheduled to release its Q2 2026 earnings on August 17, 2026, with revenue estimated at $75.4 million and an expected loss of $0.06 per share. Analysts have an average target price of $1.88, suggesting a 187.05% upside from the current price of $0.65, while GuruFocus estimates a 151.07% upside based on its GF Value. The company has an "Outperform" brokerage recommendation, despite past earnings missing expectations.
Press Release: DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo is scheduled to announce its second quarter 2026 financial results on Monday, August 17, 2026. The company will also host a conference call and webcast to discuss these results. Interested parties can access the webcast or dial in to participate.
DocGo to announce Q2 2026 results on Aug 17
DocGo Inc (NASDAQ: DCGO) is scheduled to release its second-quarter 2026 financial results after market close on Monday, August 17, 2026. The company will also host a conference call and webcast at 5:00 p.m. ET on the same day to discuss its quarterly performance. Investors can access the webcast and dial-in details through DocGo's investor relations website.
DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026
DocGo Inc. (Nasdaq: DCGO) announced that it will release its financial results for the second quarter ended June 30, 2026, after the markets close on Monday, August 17, 2026. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss these results. The company, a provider of technology-enabled mobile health and medical transportation services, has provided details for accessing the call and webcast.
DocGo (DCGO) seeks 5-day SEC extension for delayed Q2 2026 10-Q filing
DocGo Inc. has filed an NT 10-Q notification with the SEC, indicating that its Quarterly Report on Form 10-Q for the period ended June 30, 2026, will be filed late. The company stated that additional time is needed to complete and review financial statements and disclosures, and anticipates filing the report within the five-day extension period allowed under Rule 12b-25. DocGo also confirmed that all other required periodic reports over the past 12 months have been filed and does not foresee any significant change in its results of operations compared to the prior fiscal year.
DocGo Stock (DCGO) Opinions on Recent Price Movement
Social media discussions indicate that DocGo stock (DCGO) has recently declined to around $0.65 due to broader selling and short-term holders exiting positions, reflecting cautious market sentiment. DocGo reported Q1 2026 revenues of $75.6M, a 21.33% decrease year-over-year, and saw varied hedge fund activity with major institutions reducing holdings while others increased. Analysts have issued "Overweight" ratings and a median price target of $2.75 for DCGO.
DocGo Inc. (NASDAQ:DCGO) Receives Consensus Rating of "Hold" from Analysts
DocGo Inc. (NASDAQ:DCGO) has received a consensus "Hold" rating from six analysts, with an average 12-month price target of $2.375, significantly higher than its recent share price of $0.62. The company exceeded revenue expectations for its latest quarter, reporting $75.55 million against an estimated $72.48 million, but missed on earnings per share, posting a loss of $0.12 compared to an estimated loss of $0.02. Institutional investors and hedge funds own 56.44% of DocGo's shares.
DocGo Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and encouraging investors who suffered losses exceeding $100,000 between November 8, 2022, and September 17, 2023, to contact them. The investigation follows allegations that DocGo made false or misleading statements regarding its executive hiring processes, the efficacy of its services, and its financial prospects, leading to significant stock price drops after revelations about its migrant relocation contract and CEO's falsified biography. Investors have until December 26, 2023, to seek the role of lead plaintiff in the federal securities class action lawsuit.
DocGo Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and reminds investors who suffered losses between November 8, 2022, and September 17, 2023, of the December 26, 2023, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that DocGo made false and misleading statements regarding its executive hiring, the efficacy of its services in the New York City migrant relocation contract, and the professional background of its former CEO, Anthony Capone, leading to significant stock price drops following negative reports and his resignation. Investors are encouraged to contact the firm to discuss their legal rights.
DocGo Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and reminds investors of the December 26, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that DocGo made false and misleading statements regarding its executive hiring processes, the efficacy of its mobile health services, and faced significant reputational and regulatory scrutiny. These issues led to a decline in DocGo's stock price following reports about its migrant relocation contract, an investigation by the New York Attorney General, rejection of the contract by the New York City Comptroller, and the resignation of its CEO due to falsified credentials.
DocGo Granted Nasdaq Extension to Regain Listing Compliance
DocGo (DCGO) has received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. Shareholders have already approved a potential reverse stock split at a ratio between 1-for-5 and 1-for-10 to help achieve this. TipRanks' AI Analyst, Spark, rates DCGO as Neutral, citing deteriorating profitability and cash flow, despite some positive factors like raised revenue guidance and corporate actions.
DocGo Number of Employees 2026 | Employee Count & Headcount Data
DocGo, Inc. (NASDAQ: DCGO) has approximately 3,548 total employees worldwide as of March 2026, a 16.7% decline from 2023. The company is actively hiring, with 271 active job postings in 2026, and its workforce is primarily concentrated in the United States, followed by the United Kingdom and the Philippines. The average employee salary at DocGo is $63,167, with overall employee sentiment being negative and declining.
DocGo Granted Nasdaq Extension to Regain Listing Compliance
DocGo (DCGO) has received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. Shareholders have already approved a reverse stock split option to help the company meet this threshold. Analysts currently rate DCGO as a "Buy" with a $2.50 price target, though TipRanks' AI Analyst, Spark, notes concerns about profitability and cash flow.
DocGo | ARS: Annual Report to Security Holders
This document is an Annual Report to Security Holders (ARS) for DocGo. It indicates that the report is available for review, and includes a link to access the full SEC filing for detailed financial and operational information.
DocGo Shareholder Action Reminder
Faruqi & Faruqi, LLP reminds investors who suffered losses exceeding $50,000 in DocGo securities between November 8, 2022, and September 17, 2023, to contact the firm regarding a federal securities class action lawsuit. The lawsuit alleges that DocGo made false and misleading statements concerning executive hiring processes, the efficacy of its services for a $432 million migrant relocation contract, and faced significant reputational scrutiny due to issues with the contract and its former CEO's falsified biography. Investors have until December 26, 2023, to seek the role of lead plaintiff.
DocGo Disclosed Failure to Satisfy a Continued Listing Rule or Standard
DocGo (DCGO) received an extension from Nasdaq until January 25, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company needs its stock to close at or above $1.00 for at least 10 consecutive business days, and a reverse stock split is a potential option authorized by shareholders. This information is based on an SEC filing from July 31, 2026.
DocGo Inc (DCGO) Financial Health: Profitability & Balance Sheet Analysis
DocGo Inc (DCGO) currently holds a financial score of 7.25, placing it 42nd out of 75 in the Healthcare Providers & Services industry, indicating a stable financial status and high operating efficiency. Despite this, the company experienced a 21.33% year-over-year decrease in its latest quarterly revenue to $75.55 million and a 56.97% decrease in net profit. Key financial metrics related to cash and cash equivalents, total assets, liabilities, free cash flow, quality of earnings, operational efficiency, growth potential, and shareholder returns are noted, though some relevant data have not been disclosed by the company.
DocGo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and encouraging investors who lost over $100,000 between November 8, 2022, and September 17, 2023, to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that DocGo made false or misleading statements regarding executive hiring, the efficacy of its services, and the negative impact of reputational and regulatory scrutiny. These issues, including problems with a $432 million migrant relocation contract and the CEO's falsified biography, led to significant drops in DocGo's stock price.
BlackRock (DCGO holder) discloses 1.4% DocGo Inc. stake in updated ownership
BlackRock, Inc. has filed an updated ownership report for DocGo Inc. (DCGO), disclosing a beneficial ownership of 1,361,645 shares, which represents 1.4% of the company's outstanding common stock. BlackRock holds sole voting and dispositive power over these shares, and no single underlying client holds more than a 5% interest in DocGo. The filing is a SCHEDULE 13G/A, indicating a passive investment.
DocGo Inc. Revenue Breakdown – NASDAQ:DCGO
DocGo Inc. (NASDAQ: DCGO) generated $322.20 million in revenue last year, with its Transportation Services segment being the top performer at $200.77 million. The majority of the company's revenue, $268.25 million, came from the United States.
DCGO|DocGo Inc|Price:0.641|Chg%:+0.045
This article provides a comprehensive stock analysis of DocGo Inc (DCGO), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status. It notes high institutional ownership and recent analyst ratings of "Buy" with a target price suggesting significant upside. The analysis also covers the company's business model, key strengths, and risks.
DocGo Inc (DCGO) Institutional Confidence
DocGo Inc (DCGO) has an institutional shareholding score of 3.00, placing it 55th out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 43.34%, a decrease of 45.16% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.53% of outstanding shares.
DocGo Inc DCGO Cash Flow Statement
This article presents the cash flow statement for DocGo Inc (DCGO), offering a detailed financial overview including operating, investing, and financing cash flows on both a quarterly and annual basis. It highlights the company's financial soundness and stability, with key metrics like operating cash flow at $34.45M in fiscal 2025 and free cash flow at $27.02M in the latest quarter. The document also includes FAQs to clarify financial terms such as operating, investing, and financing cash flows, and their significance.
DocGo Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
This article provides a detailed company profile for DocGo Inc. (DCGO), outlining its business scope in mobile healthcare services and transportation, key financial data including market capitalization, and a list of company executives with their shareholdings. It also addresses institutional ownership, noting that 304 institutions hold shares with a combined market value of approximately $42.81 million.
DocGo Inc (DCGO) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for DocGo Inc (DCGO), noting its current valuation score of 8.45, which ranks 42 out of 75 in its industry. It highlights the company's current P/E ratio, but states that other relevant valuation data like P/B, P/S, and P/CF have not yet been disclosed by the company. The stock closed at $0.596, down 11.07%.
DocGo Inc (DCGO) Earnings Forecast: Future EPS & Revenue Growth Estimates
DocGo Inc (DCGO) has an earnings forecast score of 7.20, placing it 45th out of 75 in its industry. Analysts have set an average price target of $3.00, with an upside of 191.74%, and the stock currently holds a "Buy" rating based on 5 analysts. The company's expected revenue for the next quarter is $75.40M, and its next quarter EPS is projected at -$0.06.
Penny Stocks To Watch In July 2026
This article identifies three penny stocks—DocGo (DCGO), Intrusion (INTZ), and Phunware (PHUN)—to watch in July 2026, highlighting their financial health, operational challenges, and growth prospects. DocGo, a mobile healthcare provider, shows revenue growth despite unprofitability. Intrusion, a cybersecurity firm, is debt-free but faces liquidity issues and potential delisting. Phunware, a software platform provider, is also unprofitable but has a strong cash runway and is focusing on AI integration.
Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DocGo Inc. (DCGO) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance company transparency, accountability, and ultimately, shareholder value.
DocGo extends $26M share repurchase program expiration to Dec. 31, 2026
DocGo (DCGO) has announced an extension of its $26 million share repurchase program. The expiration date for the program has been moved from June 30, 2026, to December 31, 2026, with no other changes made. The program allows for common stock purchases through various methods and will be funded from cash, future cash flow, or borrowings.
DocGo (NASDAQ: DCGO) extends $26M share repurchase program to year-end 2026
DocGo (NASDAQ: DCGO) has extended its existing $26 million share repurchase program from June 30, 2026, to December 31, 2026. This allows the company more time to buy back up to $26 million of its common stock through various methods, including open market transactions and Rule 10b5-1 trading plans. The program can be modified or discontinued at any time, and repurchases may be funded from existing cash, future cash flow, or borrowings.
Enterprise value to EBITDA forward of DocGo Inc. – NASDAQ:DCGO
This page provides financial data for DocGo Inc. (NASDAQ: DCGO), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this specific financial ratio for the company.
Price to book forward of DocGo Inc. – NASDAQ:DCGO
This article displays the "Price to book forward" value for DocGo Inc. (NASDAQ: DCGO). It is presented within the context of financial data available on TradingView for the healthcare services company. The specific numerical value for the metric is awaited.
Price to sales forward of DocGo Inc. – NASDAQ:DCGO
The article provides a table showing the "Price to sales forward" for DocGo Inc. (NASDAQ: DCGO). It lists the period, value, change, and percentage change for this financial metric. The content highlights that the data for DocGo Inc. is available on TradingView, within the Markets section for US stocks.
Price to earnings forward of DocGo Inc. – NASDAQ:DCGO
The article provides a financial overview of DocGo Inc. (NASDAQ:DCGO), specifically mentioning its price to earnings forward metric. It indicates that no trades have occurred for the stock on the Nasdaq Stock Market as of market close. The content is primarily a data page from TradingView, focusing on financial information for the company.
DocGo Inc (DCGO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for DocGo Inc (DCGO), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the company ranks 45th out of 76 in its industry, with analysts generally recommending a "Buy" trend. The article also includes expected revenue and EPS for upcoming quarters, along with a peer comparison.
